Navigation Links
Transgenomic Reports First Quarter Financial Results
Date:5/12/2011

nts and protocols for high sensitivity detection of mutations in key cancer pathway genes. HANABI automated chromosome harvesting systems improve laboratory productivity with consistent quality compared with manual methods for cytogenetic karyotyping and FISH analyses.  Transgenomic believes there is a significant opportunity to continue growing the demand for its molecular-based testing across all business lines by leveraging core technologies, experience and expertise in biomarker analysis. In addition, the company continues to seek out and evaluate new technologies and new intellectual property to extend its offerings in molecular diagnostics and pharmacogenomic services.

Forward-Looking StatementsCertain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all st
'/>"/>

SOURCE Transgenomic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
2. Transgenomic Establishes Collaboration With the National Cancer Institute to Investigate Mitochondrial Genome and Associated Nuclear Genes in Cancer Cell Lines
3. Transgenomic and Power3 Medical Complete Agreement for Exclusive License of Neurodegenerative Biomarker Test
4. Transgenomic Signs Exclusive License for Cold-PCR Technology From the Dana-Farber Cancer Institute
5. Webcast Alert: Transgenomic Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
6. Reminder Webcast Alert: Transgenomic, Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
7. Transgenomic, Inc. Executes License Option agreement for Parkinsons Disease Diagnostic Markers with Gene Solutions, LLC
8. Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR
9. Transgenomic Reports Fourth Quarter Financial Results
10. Transgenomic to Present at the Noble Financial Sixth Annual Equity Conference - ONTRACK 2010
11. Transgenomic to Present at the Rodman & Renshaw 12th Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors of innovative ... protect their most important business assets, intellectual property ... Because of the highly-competitive nature of ... of the most litigious industry sectors of cases ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... IRVINE, Calif., May 17, 2011 CryoLife, Inc. (NYSE: ... and cardiovascular tissue processing company, today announced that it ... The acquisition of Cardiogenesis adds to ... the treatment of diffuse coronary artery disease and severe ...
... the second consecutive year, the Exergen temporal artery thermometer ... the product, according to Nielsen and Information Resources Inc. ... national brands and private label products, were compared. Along ... has risen to 20 percent of all thermometers for ...
Cached Medicine Technology:CryoLife Announces Completion of Acquisition of Cardiogenesis 2CryoLife Announces Completion of Acquisition of Cardiogenesis 3CryoLife Announces Completion of Acquisition of Cardiogenesis 4CryoLife Announces Completion of Acquisition of Cardiogenesis 5CryoLife Announces Completion of Acquisition of Cardiogenesis 6CryoLife Announces Completion of Acquisition of Cardiogenesis 7CryoLife Announces Completion of Acquisition of Cardiogenesis 8CryoLife Announces Completion of Acquisition of Cardiogenesis 9CryoLife Announces Completion of Acquisition of Cardiogenesis 10
(Date:4/24/2014)... Dartmouth has been awarded one of 30 grants from ... Lead Academic Participating Site in its new National ... a select groups of investigators charged with distributing resources ... The NCTN grant system reflects recommendations from a ... to achieve four goals:, Faster design, launch, ...
(Date:4/24/2014)... New research led by a scientist at the University ... key element in the development of the nervous system ... of breast cancer., A research team, led by ... the Department of Biology at York, has studied how ... tumours. These channels are found in the membranes of ...
(Date:4/23/2014)... clinical trials for a new experimental drug to ... Patients treated with CPX-351, a combination of the ... responses than patients treated with the standard drug ... is an aggressive blood cancer with very low ... explained Jeffrey Lancet, M.D., senior member of the ...
(Date:4/23/2014)... Va., April 23, 2014 The American Society for ... "The Role of Postoperative Radiation Therapy for Endometrial ... use of adjuvant radiation therapy in the treatment ... published in the May-June 2014 issue of ... practice journal of ASTRO. The full-length guideline is ...
(Date:4/23/2014)... N.Y. A novel compound that targets an important ... of cocaine addiction behaviors, including relapse behavior, a University ... provides strong evidence that this may be a novel ... effective medications exist., The UB research was published as ... week. , In the study, the compound, RO5263397, severely ...
Breaking Medicine News(10 mins):Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Breast cancer replicates brain development process 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2
... how low doses of arsenic, such as the levels found ... affect human physiology. In a paper published online on Dec. ... report that three different steroid hormones all show similar responses ... of arsenic on how these hormones function. ,"Since ...
... by Asher Chanan-Khan, MD, Department of Medicine, Roswell Park ... chronic lymphocytic leukemia (CLL) or diseases that no longer ... the therapy. The results of this study were published ... Clinical Oncology. ,"Chronic lymphocytic leukemia is ...
... arithmetic or to make change for a dollar. She is ... can’t write down her name clearly, nor can she cross ... person. She can sing like a nightingale although her IQ ... she knows hundreds of songs in Italian, German French, Macedonian, ...
... U.S firm Schwarz has found to be potential in reducing ... drugs - the company said on Monday following the results ... the 485-patient study were presented at the North American Regional ... 200-mg dose of the drug, lacosamide, had 14.4 percent fewer ...
... The popular hair-growth drug finasteride, taken by millions of ... antigen (PSA) test,// the standard screening test for prostate ... involving 308 men ranging in age from 40 to ... medical journal The Lancet and is scheduled to be ...
... of obesity, as a causative factor for breast cancer. It ... factor for cancer, heart disease, stroke and diabetes. Scientists have ... breast cancer. ,Latest research has indicated that having ... female hormones, the presence of which elevates the risk of ...
Cached Medicine News:Health News:Low Doses Of Arsenic Have Broad Impact On Hormone Activity – Says A Researc 2Health News:Low Doses Of Arsenic Have Broad Impact On Hormone Activity – Says A Researc 3Health News:Heavenly Notes from a Life Etched With Disability: The Strangest Song 2Health News:Hair-Growth Drug Artificially Lowers Psa Levels in Prostate Cancer Screening 2
... ACL 8000 is an easy-to-use, automated system ... array of assays for managing hemostatic disordersincluding ... S. Also offers reflex and rerun testing ... it's backed by our high-quality service to ...
... ACCUNET Embolic Protection System is designed to ... control when performing carotid stenting interventions. The ... filter system that utilizes rapid exchange technology ... the filter during catheter manipulations. It is ...
Four disposable disc electrodes are pre-gelled and attached to wires in red, blue, black and green. 4mil carbon film, Ag/AgCl coated. Each package contains 20 individually sealed sets of four leads....
Lancet cut ultra sharp tip for low penetration resistance. Low noise and impedance level giving you a clear and reliable signal. Stainless steel needle, color coded attached lead wires. Needles sold ...
Medicine Products: